In largest head-to-head randomized clinical trial evaluating the two medicines, Dovato (DTG/3TC) met the primary endpoint, demonstrating sustained non-inferior efficacy versus Biktarvy (BIC/FTC/TAF) ...

Like a dolutegravir-based three-drug regimen, Dovato uses two drugs to inhibit the viral cycle at two different sites. INIs, like dolutegravir, inhibit HIV replication by preventing the viral DNA from ...

The MarketWatch News Department was not involved in the creation of this content. -- Dovato is now the first and only oral, two-drug, single-tablet regimen available for people aged 12 and older ...

LONDON--(BUSINESS WIRE)-- ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, announces 48-week findings from PASO DOBLE (GeSIDA 11720 ...

Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain experienced by participants taking Dovato ...

(Reuters) - GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a ...

Data presented at HIV Glasgow from the DOLCE study demonstrates our commitment to offering effective 2-drug HIV regimens, for people living with advanced HIV A post-hoc analysis shows the 2-drug ...

Credit: ViiV Healthcare. The new blister pack is a monthly 30-count box containing 5 sheets of tablets; each sheet is perforated and is about "the size of a credit card" offering more discreet ...

The MarketWatch News Department was not involved in the creation of this content. -- Largest head-to-head randomised clinical trial between DTG/3TC and BIC/FTC/TAF, conducted by SEIMC-GeSIDA ...